<DOC>
	<DOC>NCT00135408</DOC>
	<brief_summary>The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.</brief_summary>
	<brief_title>A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Histologic or cytologic diagnosis of unresectable Stage III or IV malignant melanoma (excluding ocular melanoma) Flexible Sigmoidoscopy and colonic biopsy required Patients with active, untreated central nervous system metastasis. Patients with autoimmune disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Unresectable Stage III or IV Malignant Melanoma</keyword>
</DOC>